Results 71 to 80 of about 46,872 (214)
Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
Frontiers in Pharmacology, 2019 The effect of anti-diabetic medications on bone metabolism has received increasing attention, considering that type 2 diabetes mellitus is a common metabolic disorder with adverse effects on bone metabolism.
Yangli Ye +5 more
doaj +1 more source
New Diabetes Therapies and Diabetic Kidney Disease Progression:the Role of SGLT-2 Inhibitors [PDF]
, 2018 Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease.
Dekkers, Claire C. J. +2 more
core +7 more sources
Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms [PDF]
, 2016 Diabetes mellitus (DM) is the major cause of end-stage renal disease (ESRD) globally, and novel treatments are urgently needed. Current therapeutic approaches for diabetic nephropathy (DN) are focussing on blood pressure control with inhibitors of the ...
Coward, RJ, Gnudi, L, Long, DA
core +1 more source
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality? [PDF]
, 2017 The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial
Rossello, X, Yellon, DM
core +1 more source
SGLT2 inhibitors in cardiovascular medicine [PDF]
European Heart Journal - Cardiovascular Pharmacotherapy, 2021 Varzideh, Fahimeh +2 more
openaire +3 more sources
Pharmaceutics, 2020 Since sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced blood glucose level by inhibiting renal tubular glucose reabsorption mediated by SGLT2, we aimed to investigate the pharmacokinetics and kidney distribution of DWP16001, a novel SGLT2 ...
Min-Koo Choi +5 more
doaj +1 more source
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. [PDF]
, 2018 The concentration of glucose in plasma is held within narrow limits (4-10 mmol/l), primarily to ensure fuel supply to the brain. Kidneys play a role in glucose homeostasis in the body by ensuring that glucose is not lost in the urine.
Ghezzi, Chiara +2 more
core
SGLT2 inhibitors: expanding their Empire beyond diabetes [PDF]
The Lancet Diabetes & Endocrinology, 2021 Muskiet, Marcel H. A. +2 more
openaire +3 more sources
Cardiovascular DiabetologyBackground Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited treatments.
Arif Albulushi +5 more
doaj +1 more source
Canagliflozin: A Review in Type 2 Diabetes. [PDF]
, 2017 peer reviewedCanagliflozin (Invokana(R)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D).
Deeks, Emma D., Scheen, André
core +2 more sources